PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets… Read more
PlexBio Co., Ltd. (6572) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.222x
Based on the latest financial reports, PlexBio Co., Ltd. (6572) has a cash flow conversion efficiency ratio of -0.222x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-72.73 Million) by net assets (NT$327.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PlexBio Co., Ltd. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how PlexBio Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PlexBio Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PlexBio Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SY PUBLIC UTIL -H- (SH3.SG)
STU:SH3
|
-0.353x |
|
Beauty Skin Corp.
KQ:406820
|
-0.066x |
|
Texmo Pipes and Products Limited
NSE:TEXMOPIPES
|
-0.079x |
|
HeveaBoard Bhd
KLSE:5095
|
-0.003x |
|
LBT Innovations Ltd
AU:LBT
|
-0.961x |
|
Apollo Silver Corp
OTCQB:APGOF
|
-0.191x |
|
Infrared Cameras Holdings Inc
NASDAQ:MSAI
|
-0.218x |
|
Solueta Co Ltd
KQ:154040
|
0.117x |
Annual Cash Flow Conversion Efficiency for PlexBio Co., Ltd. (2020–2024)
The table below shows the annual cash flow conversion efficiency of PlexBio Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$374.41 Million | NT$-5.06 Million | -0.014x | +80.42% |
| 2023-12-31 | NT$424.40 Million | NT$-29.27 Million | -0.069x | +53.72% |
| 2022-12-31 | NT$479.43 Million | NT$-71.44 Million | -0.149x | +5.58% |
| 2021-12-31 | NT$534.32 Million | NT$-84.33 Million | -0.158x | +5.62% |
| 2020-12-31 | NT$662.49 Million | NT$-110.79 Million | -0.167x | -- |